Cargando…

Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats

In this study was evaluated the chronic cardiac effects of a formulation developed by including angiotensin(Ang)-(1–7) in hydroxypropyl β-cyclodextrin (HPβCD), in infarcted rats. Myocardial infarction (MI) was induced by left coronary artery occlusion. HPβCD/Ang-(1–7) was administered for 60 days (7...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques, Fúlvia D., Melo, Marcos B., Souza, Leandro E., Irigoyen, Maria Claúdia C., Sinisterra, Rúben D., de Sousa, Frederico B., Savergnini, Sílvia Q., Braga, Vinícius B. A., Ferreira, Anderson J., Santos, Robson A. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296310/
https://www.ncbi.nlm.nih.gov/pubmed/22482038
http://dx.doi.org/10.1155/2012/795452
_version_ 1782225705981968384
author Marques, Fúlvia D.
Melo, Marcos B.
Souza, Leandro E.
Irigoyen, Maria Claúdia C.
Sinisterra, Rúben D.
de Sousa, Frederico B.
Savergnini, Sílvia Q.
Braga, Vinícius B. A.
Ferreira, Anderson J.
Santos, Robson A. S.
author_facet Marques, Fúlvia D.
Melo, Marcos B.
Souza, Leandro E.
Irigoyen, Maria Claúdia C.
Sinisterra, Rúben D.
de Sousa, Frederico B.
Savergnini, Sílvia Q.
Braga, Vinícius B. A.
Ferreira, Anderson J.
Santos, Robson A. S.
author_sort Marques, Fúlvia D.
collection PubMed
description In this study was evaluated the chronic cardiac effects of a formulation developed by including angiotensin(Ang)-(1–7) in hydroxypropyl β-cyclodextrin (HPβCD), in infarcted rats. Myocardial infarction (MI) was induced by left coronary artery occlusion. HPβCD/Ang-(1–7) was administered for 60 days (76 μg/Kg/once a day/gavage) starting immediately before infarction. Echocardiography was utilized to evaluate usual cardiac parameters, and radial strain method was used to analyze the velocity and displacement of myocardial fibers at initial time and 15, 30, and 50 days after surgery. Real-time PCR was utilized to evaluate the fibrotic signaling involved in the remodeling process. Once-a-day oral HPβCD/Ang-(1–7) administration improved the cardiac function and reduced the deleterious effects induced by MI on TGF-β and collagen type I expression, as well as on the velocity and displacement of myocardial fibers. These findings confirm cardioprotective effects of Ang-(1–7) and indicate HPβCD/Ang-(1–7) as a feasible formulation for long-term oral administration of this heptapeptide.
format Online
Article
Text
id pubmed-3296310
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32963102012-04-05 Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats Marques, Fúlvia D. Melo, Marcos B. Souza, Leandro E. Irigoyen, Maria Claúdia C. Sinisterra, Rúben D. de Sousa, Frederico B. Savergnini, Sílvia Q. Braga, Vinícius B. A. Ferreira, Anderson J. Santos, Robson A. S. Int J Hypertens Research Article In this study was evaluated the chronic cardiac effects of a formulation developed by including angiotensin(Ang)-(1–7) in hydroxypropyl β-cyclodextrin (HPβCD), in infarcted rats. Myocardial infarction (MI) was induced by left coronary artery occlusion. HPβCD/Ang-(1–7) was administered for 60 days (76 μg/Kg/once a day/gavage) starting immediately before infarction. Echocardiography was utilized to evaluate usual cardiac parameters, and radial strain method was used to analyze the velocity and displacement of myocardial fibers at initial time and 15, 30, and 50 days after surgery. Real-time PCR was utilized to evaluate the fibrotic signaling involved in the remodeling process. Once-a-day oral HPβCD/Ang-(1–7) administration improved the cardiac function and reduced the deleterious effects induced by MI on TGF-β and collagen type I expression, as well as on the velocity and displacement of myocardial fibers. These findings confirm cardioprotective effects of Ang-(1–7) and indicate HPβCD/Ang-(1–7) as a feasible formulation for long-term oral administration of this heptapeptide. Hindawi Publishing Corporation 2012 2012-02-09 /pmc/articles/PMC3296310/ /pubmed/22482038 http://dx.doi.org/10.1155/2012/795452 Text en Copyright © 2012 Fúlvia D. Marques et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Marques, Fúlvia D.
Melo, Marcos B.
Souza, Leandro E.
Irigoyen, Maria Claúdia C.
Sinisterra, Rúben D.
de Sousa, Frederico B.
Savergnini, Sílvia Q.
Braga, Vinícius B. A.
Ferreira, Anderson J.
Santos, Robson A. S.
Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats
title Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats
title_full Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats
title_fullStr Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats
title_full_unstemmed Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats
title_short Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats
title_sort beneficial effects of long-term administration of an oral formulation of angiotensin-(1–7) in infarcted rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296310/
https://www.ncbi.nlm.nih.gov/pubmed/22482038
http://dx.doi.org/10.1155/2012/795452
work_keys_str_mv AT marquesfulviad beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats
AT melomarcosb beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats
AT souzaleandroe beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats
AT irigoyenmariaclaudiac beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats
AT sinisterrarubend beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats
AT desousafredericob beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats
AT savergninisilviaq beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats
AT bragaviniciusba beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats
AT ferreiraandersonj beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats
AT santosrobsonas beneficialeffectsoflongtermadministrationofanoralformulationofangiotensin17ininfarctedrats